At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 509 enrolled
Drug / intervention
Olaratumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma
In Brief
A Phase 3 clinical trial evaluating Olaratumab, Doxorubicin, and 1 other intervention for Soft Tissue Sarcoma. Completed, enrolled 509 participants across 114 sites in 25 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Sarcoma
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Poland, Russia, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartSep 2015
Primary CompletionDec 2018
Study CompletionJun 2024
TodayJul 2026
First PostedMay 22, 2015
Enrollment StartSep 14, 2015
Primary CompletionDec 5, 2018
Study CompletionJun 27, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.1 years ago
Interventions
Olaratumabdrug
Administered IV
Doxorubicindrug
Administered IV
Placebodrug
Administered IV